These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 25813728

  • 1. Genetically at-risk status and individual agency. A qualitative study on asymptomatic women living with genetic risk of breast/ovarian cancer.
    Caiata-Zufferey M.
    Soc Sci Med; 2015 May; 132():141-8. PubMed ID: 25813728
    [Abstract] [Full Text] [Related]

  • 2. [Having a child and PND/PGD access in women with a BRCA1/2 mutation? Different approach whether ill or healthy].
    Pellegrini I, Prodromou N, Coupier I, Huiart L, Moretta J, Noguès C, Julian-Reynier C.
    Bull Cancer; 2014 Nov; 101(11):1001-8. PubMed ID: 25418592
    [Abstract] [Full Text] [Related]

  • 3. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N, Foster C, Eeles R, Ardern-Jones A, Watson M.
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [Abstract] [Full Text] [Related]

  • 4. The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers.
    Dagan E, Goldblatt H.
    Women Health; 2009 Jun; 49(4):263-79. PubMed ID: 19753503
    [Abstract] [Full Text] [Related]

  • 5. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.
    Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO.
    Genet Med; 2015 Sep; 17(9):726-32. PubMed ID: 25503500
    [Abstract] [Full Text] [Related]

  • 6. Conditions and consequences of a BRCA mutation in young, single women of childbearing age.
    Hamilton R, Hurley KE.
    Oncol Nurs Forum; 2010 Sep; 37(5):627-34. PubMed ID: 20797954
    [Abstract] [Full Text] [Related]

  • 7. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L, Morrison PJ, McCaughan E, Fitzsimons D.
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [Abstract] [Full Text] [Related]

  • 8. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    Werner-Lin A, Hoskins LM, Doyle MH, Greene MH.
    Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
    [Abstract] [Full Text] [Related]

  • 9. Toward a new understanding of risk perception among young female BRCA1/2 "previvors".
    Hoskins LM, Roy KM, Greene MH.
    Fam Syst Health; 2012 Mar; 30(1):32-46. PubMed ID: 22429077
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Being young, female, and BRCA positive.
    Hamilton R.
    Am J Nurs; 2012 Oct; 112(10):26-31, quiz 46, 32. PubMed ID: 22982855
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
    Dean M.
    Soc Sci Med; 2016 Aug; 163():21-7. PubMed ID: 27376595
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Psychological adjustment among male partners in response to women's breast/ovarian cancer risk: a theoretical review of the literature.
    Sherman KA, Kasparian NA, Mireskandari S.
    Psychooncology; 2010 Jan; 19(1):1-11. PubMed ID: 19472298
    [Abstract] [Full Text] [Related]

  • 16. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Esplen MJ, Hunter J, Leszcz M, Warner E, Narod S, Metcalfe K, Glendon G, Butler K, Liede A, Young MA, Kieffer S, DiProspero L, Irwin E, Wong J.
    Cancer; 2004 Nov 15; 101(10):2327-40. PubMed ID: 15478194
    [Abstract] [Full Text] [Related]

  • 17. Five families living with hereditary breast and ovarian cancer risk.
    Norris J, Spelic SS, Snyder C, Tinley S.
    Clin J Oncol Nurs; 2009 Feb 15; 13(1):73-80. PubMed ID: 19193551
    [Abstract] [Full Text] [Related]

  • 18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
    Gynecol Oncol; 2005 May 15; 97(2):457-67. PubMed ID: 15863145
    [Abstract] [Full Text] [Related]

  • 19. The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
    Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti MA.
    Clin Genet; 2014 Jan 15; 85(1):7-15. PubMed ID: 24117034
    [Abstract] [Full Text] [Related]

  • 20. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    Maheu C, Bouhnik AD, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Julian-Reynier C.
    Psychooncology; 2014 Apr 15; 23(4):420-7. PubMed ID: 24127257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.